Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease

First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease

(2014) Christian Hölscher   Alzheimers & Dementia

The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease

(2014) Christian Hölscher   Alzheimers & Dementia

Transcriptional Analysis of Apoptotic Cerebellar Granule Neurons Following Rescue by Gastric Inhibitory Polypeptide

(2014) Barbara Maino et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Association of diabetes with amnestic and nonamnestic mild cognitive impairment

(2013) Rosebud O. Roberts et al.   Alzheimers & Dementia

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

(2013) Jessica Freiherr et al.   CNS DRUGS

Gut hormones as therapeutic agents in treatment of diabetes and obesity

(2013) Tricia Tan et al.   CURRENT OPINION IN PHARMACOLOGY

Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease

(2011) Christian Hölscher   BIOCHEMICAL SOCIETY TRANSACTIONS

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity

(2011) Victor A. Gault et al.   CLINICAL SCIENCE

Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats

(2011) Vladimer Darsalia et al.   CLINICAL SCIENCE

The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis

(2011) Jie Zhao et al.   Journal of Neuroinflammation

Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases

(2010) Cláudia P. Figueiredo et al.   BEHAVIOURAL PHARMACOLOGY

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

(2010) D. W. Porter et al.   DIABETES OBESITY & METABOLISM

Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention

(2009) Malú G. Tansey et al.   NEUROBIOLOGY OF DISEASE